Christopher Halliday

949 total citations
21 papers, 560 citations indexed

About

Christopher Halliday is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Christopher Halliday has authored 21 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Surgery. Recurrent topics in Christopher Halliday's work include Protein Degradation and Inhibitors (12 papers), Peptidase Inhibition and Analysis (5 papers) and HIV Research and Treatment (3 papers). Christopher Halliday is often cited by papers focused on Protein Degradation and Inhibitors (12 papers), Peptidase Inhibition and Analysis (5 papers) and HIV Research and Treatment (3 papers). Christopher Halliday collaborates with scholars based in United States, United Kingdom and Canada. Christopher Halliday's co-authors include Brigitte Nerlich, Ewelina Kulikowski, Norman C.W. Wong, Michael Sweeney, Dean Gilham, Sylwia Wasiak, Laura Tsujikawa, Jan Johansson, Jan O. Johansson and Kamyar Kalantar‐Zadeh and has published in prestigious journals such as Journal of the American College of Cardiology, Arteriosclerosis Thrombosis and Vascular Biology and Atherosclerosis.

In The Last Decade

Christopher Halliday

21 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Halliday United States	11	282	97	85	69	62	21	560
Mi-Kyung Park South Korea	10	138 0.5×	24 0.2×	37 0.4×	29 0.4×	98 1.6×	29	576
Ana Paula Silva Portugal	14	59 0.2×	45 0.5×	40 0.5×	85 1.2×	109 1.8×	56	577
Pratibha Nair United Arab Emirates	12	221 0.8×	39 0.4×	76 0.9×	46 0.7×	36 0.6×	47	735
Ermal Bojdani United States	7	251 0.9×	219 2.3×	14 0.2×	25 0.4×	12 0.2×	16	685
Huib de Jong Netherlands	12	50 0.2×	47 0.5×	24 0.3×	67 1.0×	7 0.1×	22	394
Nathalie de Lourdes Souza Dewulf Brazil	13	516 1.8×	14 0.1×	10 0.1×	76 1.1×	66 1.1×	33	833
Kyung Sook Park South Korea	14	165 0.6×	13 0.1×	60 0.7×	43 0.6×	19 0.3×	43	663
Ville Autio Finland	18	274 1.0×	82 0.8×	25 0.3×	189 2.7×	16 0.3×	26	999
Kyriaki Michailidou Cyprus	15	202 0.7×	16 0.2×	26 0.3×	31 0.4×	31 0.5×	57	601
Daniela Turchetti Italy	21	397 1.4×	18 0.2×	8 0.1×	69 1.0×	50 0.8×	94	1.2k

Countries citing papers authored by Christopher Halliday

Since Specialization

Citations

This map shows the geographic impact of Christopher Halliday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Halliday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Halliday more than expected).

Fields of papers citing papers by Christopher Halliday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Halliday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Halliday. The network helps show where Christopher Halliday may publish in the future.

Co-authorship network of co-authors of Christopher Halliday

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Halliday. A scholar is included among the top collaborators of Christopher Halliday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Halliday. Christopher Halliday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schwartz, Gregory G., Stephen J. Nicholls, Peter P. Tóth, et al.. (2021). Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology. 20(1). 125–125. 16 indexed citations

Halliday, Christopher, et al.. (2021). Mapping Savanna Wildfires in Southern Belize Using Sentinel-1 SAR and Object Based Image Analysis. 17?022. 8420–8423. 1 indexed citations

Wasiak, Sylwia, Dean Gilham, Christopher Halliday, et al.. (2019). Abstract 671: Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients. Arteriosclerosis Thrombosis and Vascular Biology. 1 indexed citations

Tsujikawa, Laura, Li Fu, Brooke D. Rakai, et al.. (2019). APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS. Journal of the American College of Cardiology. 73(9). 2063–2063. 1 indexed citations

Haarhaus, Mathias, Kausik K. Ray, Stephen J. Nicholls, et al.. (2019). Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 290. 59–65. 31 indexed citations

Tsujikawa, Laura, Li Fu, Christopher Halliday, et al.. (2019). Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clinical Epigenetics. 11(1). 102–102. 90 indexed citations

Kalantar‐Zadeh, Kamyar, Carmine Zoccali, Srinivasan Beddhu, et al.. (2019). FP330APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE PATIENTS. Nephrology Dialysis Transplantation. 34(Supplement_1). 1 indexed citations

Kulikowski, Ewelina, Christopher Halliday, Jan Johansson, et al.. (2018). Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease. Kidney & Blood Pressure Research. 43(2). 449–457. 41 indexed citations

Gilham, Dean, Laura Tsujikawa, Christopher D. Sarsons, et al.. (2018). Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 280. 75–84. 49 indexed citations

10.

Unger, Stefan, et al.. (2018). Blood gas analysis as a marker of severity in acute bronchiolitis. OA3605–OA3605. 1 indexed citations

11.

Wasiak, Sylwia, Laura Tsujikawa, Christopher Halliday, et al.. (2017). Benefit of Apabetalone on Plasma Proteins in Renal Disease. Kidney International Reports. 3(3). 711–721. 32 indexed citations

12.

Wong, Norman C.W., Ewelina Kulikowski, Cyrus Calosing, et al.. (2017). APABETALONE (RVX-208) LOWERS CARDIOVASCULAR DISEASE (CVD) IN DIABETES MELLITUS BY A MECHANISM INVOLVING MICROBIOME MEDIATED ACTIVITY ON THE COMPLEMENT PATHWAY. Journal of the American College of Cardiology. 69(11). 2009–2009. 1 indexed citations

13.

Kulikowski, Ewelina, et al.. (2017). SP425EFFECTS OF APABETALONE (RVX-208) ON SERUM ALBUMIN IN SUBJECTS WITH CVD, DIABETES AND CHRONIC KIDNEY DISEASE; A POST-HOC ANALYSIS OF THE ASSURE AND SUSTAIN CLINICAL TRIALS. Nephrology Dialysis Transplantation. 32(suppl_3). iii264–iii264. 2 indexed citations

14.

Wasiak, Sylwia, Dean Gilham, Laura Tsujikawa, et al.. (2017). Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208). Journal of Cardiovascular Translational Research. 10(4). 337–347. 43 indexed citations

15.

Wasiak, Sylwia, Dean Gilham, Laura Tsujikawa, et al.. (2016). Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes. Data in Brief. 8. 1280–1288. 15 indexed citations

16.

Gilham, Dean, Sylwia Wasiak, Laura Tsujikawa, et al.. (2016). RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 247. 48–57. 88 indexed citations

17.

Wong, Norman C.W., Kamyar Kalantar‐Zadeh, Ewelina Kulikowski, et al.. (2016). SP071APABETALONE (RVX-208), A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, DECREASES ABUNDANCE AND ACTIVITY OF COMPLEMENT PROTEINS IN VITRO, IN MICE AND IN CLINICAL STUDIES. Nephrology Dialysis Transplantation. 31(suppl_1). i109–i109. 3 indexed citations

18.

Unger, Stefan, Christopher Halliday, & Steve Cunningham. (2016). Blood gas analysis in acute bronchiolitis – Who and when?. PA1596–PA1596. 1 indexed citations

19.

Wong, Norman C.W., Ewelina Kulikowski, Sylwia Wasiak, et al.. (2015). Abstract 338: Effects of RVX-208 a Selective Bromodomain Extra-Terminal Protein Inhibitor Beyond Raising ApoA-I/HDL.. Arteriosclerosis Thrombosis and Vascular Biology. 35(suppl_1). 1 indexed citations

20.

Nerlich, Brigitte & Christopher Halliday. (2007). Avian flu: the creation of expectations in the interplay between science and the media. Sociology of Health & Illness. 29(1). 46–65. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact